LIVIVO - The Search Portal for Life Sciences

zur deutschen Oberfläche wechseln
Advanced search

Search results

Result 1 - 10 of total 109

Search options

  1. Article ; Online: Editorial: thiopurines in the multidrug era-time to rescue our memories over half a century of experience.

    Gros, Beatriz / Rodríguez-Lago, Iago

    Alimentary pharmacology & therapeutics

    2022  Volume 56, Issue 6, Page(s) 1080–1081

    MeSH term(s) Azathioprine/therapeutic use ; Humans ; Mercaptopurine
    Chemical Substances Mercaptopurine (E7WED276I5) ; Azathioprine (MRK240IY2L)
    Language English
    Publishing date 2022-08-20
    Publishing country England
    Document type Editorial ; Research Support, Non-U.S. Gov't ; Comment
    ZDB-ID 639012-2
    ISSN 1365-2036 ; 0269-2813 ; 0953-0673
    ISSN (online) 1365-2036
    ISSN 0269-2813 ; 0953-0673
    DOI 10.1111/apt.17164
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  2. Article ; Online: Surfing the web as a patient with IBD: New horizons.

    Rodríguez-Lago, Iago / Catalan-Serra, Ignacio / Barreiro-de Acosta, Manuel

    United European gastroenterology journal

    2023  Volume 11, Issue 7, Page(s) 592–594

    MeSH term(s) Humans ; Crohn Disease ; Colitis, Ulcerative
    Language English
    Publishing date 2023-07-06
    Publishing country England
    Document type Editorial ; Research Support, Non-U.S. Gov't ; Comment
    ZDB-ID 2728585-6
    ISSN 2050-6414 ; 2050-6406
    ISSN (online) 2050-6414
    ISSN 2050-6406
    DOI 10.1002/ueg2.12437
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  3. Article: Editorial: Current trends and future management of IBD.

    Estevinho, María Manuela / Lobatón, Triana / Noor, Nurulamin / Rodríguez-Lago, Iago

    Frontiers in medicine

    2023  Volume 10, Page(s) 1195201

    Language English
    Publishing date 2023-04-13
    Publishing country Switzerland
    Document type Editorial
    ZDB-ID 2775999-4
    ISSN 2296-858X
    ISSN 2296-858X
    DOI 10.3389/fmed.2023.1195201
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  4. Article ; Online: Environmental Exposure to Trace Elements and Heavy Metals Preceding the Clinical Onset of Inflammatory Bowel Disease.

    Rodríguez-Lago, Iago / Cabriada, José Luis / Rodríguez, Ainhoa / Barreiro-de Acosta, Manuel

    Crohn's & colitis 360

    2024  Volume 6, Issue 1, Page(s) otae018

    Abstract: Background: The immune dysregulation underlying inflammatory bowel disease (IBD) can start years before the diagnosis, but the role of triggering factors and environmental exposures during this period is still uncertain.: Methods: This single-center ... ...

    Abstract Background: The immune dysregulation underlying inflammatory bowel disease (IBD) can start years before the diagnosis, but the role of triggering factors and environmental exposures during this period is still uncertain.
    Methods: This single-center case-control study included asymptomatic subjects with an incidental diagnosis of IBD during the colorectal cancer screening program. Twenty-two minerals and 17 metals were determined at diagnosis in hair samples and compared 1:2 to healthy controls.
    Results: Six patients with preclinical IBD (3 ulcerative colitis, 67% left-sided; 3 Crohn's disease, 100% ileal, 67% inflammatory behavior) and 13 healthy non-IBD controls were included. No relevant occupational exposures were identified. We found statistically significant higher levels of sodium, potassium, and boron among cases compared to controls; while lower levels of zinc, uranium, copper, and germanium were observed.
    Conclusions: A range of environmental exposures can be identified during the preclinical phase of IBD, but their relationship with the symptomatic onset and disease progression should be further explored.
    Language English
    Publishing date 2024-03-14
    Publishing country England
    Document type Journal Article
    ISSN 2631-827X
    ISSN (online) 2631-827X
    DOI 10.1093/crocol/otae018
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  5. Article ; Online: Mild to moderate ulcerative colitis: Call me by my name.

    Rodríguez-Lago, Iago / Barreiro-de Acosta, Manuel

    United European gastroenterology journal

    2022  Volume 10, Issue 9, Page(s) 919–920

    Language English
    Publishing date 2022-08-28
    Publishing country England
    Document type Editorial
    ZDB-ID 2728585-6
    ISSN 2050-6414 ; 2050-6406
    ISSN (online) 2050-6414
    ISSN 2050-6406
    DOI 10.1002/ueg2.12299
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  6. Article: How to Optimize Treatment With Ustekinumab in Inflammatory Bowel Disease: Lessons Learned From Clinical Trials and Real-World Data.

    Gutiérrez, Ana / Rodríguez-Lago, Iago

    Frontiers in medicine

    2021  Volume 8, Page(s) 640813

    Abstract: Ustekinumab is a fully human IgG1 monoclonal antibody that has been approved for the treatment of moderate to severe Crohn's disease, and more recently moderate to severe ulcerative colitis. It binds with high affinity to the p40 subunit of human ... ...

    Abstract Ustekinumab is a fully human IgG1 monoclonal antibody that has been approved for the treatment of moderate to severe Crohn's disease, and more recently moderate to severe ulcerative colitis. It binds with high affinity to the p40 subunit of human interleukin-12 and 23. This mechanism of action prevents the bioactivity of both interleukins, thus precluding their interaction with the cell surface receptor protein. The pivotal clinical trials (UNITI-1, UNITI-2 and IM-UNITI) demonstrated its clinical efficacy and safety, in naïve patients and also in those previously exposed to immunosuppressants and/or biologics. There is now an extensive experience with its use worldwide, corroborating its favorable profile even in patients with refractory disease. However, the number of medical treatment options available in inflammatory bowel disease are still limited. Hence, we should prioritize the treatments that have a greater probability of response in an individual patient. Our aim was to review and summarize all the available literature regarding the potential predictors of response to ustekinumab that can increase the success rate with this therapy in clinical practice.
    Language English
    Publishing date 2021-01-28
    Publishing country Switzerland
    Document type Journal Article ; Review
    ZDB-ID 2775999-4
    ISSN 2296-858X
    ISSN 2296-858X
    DOI 10.3389/fmed.2021.640813
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  7. Article ; Online: Modifying the natural history of gastrointestinal diseases in Europe as a result of early diagnosis: From eosinophilic esophagitis to inflammatory bowel disease.

    Molina-Infante, Javier / Rodríguez-Lago, Iago

    United European gastroenterology journal

    2022  Volume 10, Issue 7, Page(s) 612–613

    MeSH term(s) Enteritis ; Eosinophilia ; Eosinophilic Esophagitis/diagnosis ; Eosinophilic Esophagitis/epidemiology ; Gastritis ; Humans ; Inflammatory Bowel Diseases/diagnosis ; Inflammatory Bowel Diseases/epidemiology
    Language English
    Publishing date 2022-05-25
    Publishing country England
    Document type Editorial ; Research Support, Non-U.S. Gov't ; Comment
    ZDB-ID 2728585-6
    ISSN 2050-6414 ; 2050-6406
    ISSN (online) 2050-6414
    ISSN 2050-6406
    DOI 10.1002/ueg2.12256
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  8. Article ; Online: How to Optimize Treatment With Ustekinumab in Inflammatory Bowel Disease

    Ana Gutiérrez / Iago Rodríguez-Lago

    Frontiers in Medicine, Vol

    Lessons Learned From Clinical Trials and Real-World Data

    2021  Volume 8

    Abstract: Ustekinumab is a fully human IgG1 monoclonal antibody that has been approved for the treatment of moderate to severe Crohn's disease, and more recently moderate to severe ulcerative colitis. It binds with high affinity to the p40 subunit of human ... ...

    Abstract Ustekinumab is a fully human IgG1 monoclonal antibody that has been approved for the treatment of moderate to severe Crohn's disease, and more recently moderate to severe ulcerative colitis. It binds with high affinity to the p40 subunit of human interleukin-12 and 23. This mechanism of action prevents the bioactivity of both interleukins, thus precluding their interaction with the cell surface receptor protein. The pivotal clinical trials (UNITI-1, UNITI-2 and IM-UNITI) demonstrated its clinical efficacy and safety, in naïve patients and also in those previously exposed to immunosuppressants and/or biologics. There is now an extensive experience with its use worldwide, corroborating its favorable profile even in patients with refractory disease. However, the number of medical treatment options available in inflammatory bowel disease are still limited. Hence, we should prioritize the treatments that have a greater probability of response in an individual patient. Our aim was to review and summarize all the available literature regarding the potential predictors of response to ustekinumab that can increase the success rate with this therapy in clinical practice.
    Keywords Crohn's disease ; predictive factors ; ulcerative colitis ; ustekinumab ; biological therapy ; Medicine (General) ; R5-920
    Subject code 610
    Language English
    Publishing date 2021-01-01T00:00:00Z
    Publisher Frontiers Media S.A.
    Document type Article ; Online
    Database BASE - Bielefeld Academic Search Engine (life sciences selection)

    More links

    Kategorien

  9. Article ; Online: Editorial

    María Manuela Estevinho / Triana Lobatón / Nurulamin Noor / Iago Rodríguez-Lago

    Frontiers in Medicine, Vol

    Current trends and future management of IBD

    2023  Volume 10

    Keywords Crohn's disease ; ulcerative colitis ; diet ; environmental factor ; endoscopy ; artificial intelligence ; Medicine (General) ; R5-920
    Language English
    Publishing date 2023-04-01T00:00:00Z
    Publisher Frontiers Media S.A.
    Document type Article ; Online
    Database BASE - Bielefeld Academic Search Engine (life sciences selection)

    More links

    Kategorien

  10. Article ; Online: Risk of Depression During the Natural History of Inflammatory Bowel Disease: The Phantom Menace.

    Rodríguez-Lago, Iago / Barreiro-de Acosta, Manuel

    Inflammatory bowel diseases

    2021  Volume 27, Issue 9, Page(s) e99–e100

    MeSH term(s) Colitis ; Colitis, Ulcerative ; Depression/epidemiology ; Depression/etiology ; Humans ; Inflammatory Bowel Diseases/complications ; Inflammatory Bowel Diseases/epidemiology
    Language English
    Publishing date 2021-04-26
    Publishing country England
    Document type Journal Article ; Comment
    ZDB-ID 1340971-2
    ISSN 1536-4844 ; 1078-0998
    ISSN (online) 1536-4844
    ISSN 1078-0998
    DOI 10.1093/ibd/izab067
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

To top